NanoString Inks $45 million CDx Collaboration With Celgene

NanoString will utilize IP from a 20-gene expression assay developed by the Lymphoma/Leukemia Molecular Profiling Project (LLMP) to develop a companion diagnostic test to support clinical validation of Celgene’s REVLIMID®. NanoString could receive up to $45...

Roche Leads The Way In Biomarker-Based Test Releases

In a continuing effort to refresh the content of our research report, Commercial Trends for Biomarker-Based IVD Tests, we have begun to look at the companies that had tests cleared by 510(k) or approved by PMA during 2013. Roche led all companies in total number of...

IVD Developer Vermillion Opens CLIA Lab

Vermillion, developer of the 510(k)-cleared OVA1 test, has recently opened its own CLIA lab, called ASPiRA Labs (source: company press release). The lab will initially focus on providing the OVA1 test, but will eventually “expand to other gynecologic conditions...

IVD vs LDT Market Comparison:Key Findings

We conducted analyses of the revenue and market capitalization of publicly-traded IVD and LDT companies (see below). Here are the key takeaways and assumptions drawn from this comparison: – Dx product sales (IVD) grew at 3 times Dx service sales (LDT) from...